Haifang Du

Dr. Haifang Du

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2025 in Phytomedicine
Verified
Journal Article
Open access
ZCZifeng Chen
Zifeng Chen
XGXiang Guo
Xiang Guo
SWSimin Wu
Simin Wu
MWMaojie Wang
Maojie Wang
JWJiaqi Wu
Jiaqi Wu
QHQingchun Huang
Qingchun Huang
Angiogenesis, integral to the pathogenesis of rheumatoid arthritis (RA), contributes to the advancement of synovial hyperplasia, pannus formation, and bone destruction. The precise effect of the Huayu Tongbi formula (HT), a proven traditional Chinese medicine for RA treatment, on angiogenesis remains uncertain. To investigate the effects of HT on RA angiogenesis and the potential underlying molecular mechanisms. The target spectrum and pharmacological effects of HT were screened using network pharmacology. In vitro, RA-FLS were stimulated with CoCl2 to simulate hypoxic conditions. Human umbilical vein endothelial cells (HUVECs) were cultured with conditioned medium (CM) from RA-FLS supplemented with HT or the HIF1A inhibitor LW-6 to investigate the impact of synovial cell secretions on angiogenesis, encompassing proliferation, migration, adhesion, and lumen formation. Western blot was employed to assess protein levels of hypoxia-inducible factor 1 subunit alpha (HIF1A), vascular endothelial growth factor receptor 2 (VEGFR2), and phosphorylated VEGFR2 (p-VEGFR2). Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify VEGFA secretion, while quantitative real-time PCR (qRT‒PCR) measured mRNA expression of VEGFA, Angiopoietin 1 (ANGPT1), and ANGPT2. In vivo, a collagen-induced arthritis (CIA) model was established. Pathological changes and vessel counts were observed via hematoxylin-eosin (HE) staining, bone structure was evaluated using X-ray, mature and immature vessels were classified via immunofluorescence, and the mechanism was further verified using immunohistochemistry and ELISA. Liquid chromatography‒mass spectrometry (LC‒MS) was employed to identify the active components of HT drug-containing serum, and the potential metabolites were identified by bioinformatics analysis. Network pharmacology analysis indicated potential targets of HT in angiogenesis, correlating with HIF1A and VEGF pathways. In vitro, HT reversed proliferation, migration, and adhesion of the cell lines and suppressed luminal formation by HUVECs. HT (10 % and 15 %) effectively reduced HIF1A and VEGFA expression, attenuated VEGFR2 levels and its phosphorylation, and downregulated VEGFA, ANGPT1, and ANGPT2 mRNA levels. In vivo, HT mitigated inflammation and bone destruction, reduced immature (CD31+/α-SMA-) and mature (CD31+/α-SMA+) vessel counts in the synovium, and inhibited the HIF1A-VEGFA-ANGPT axis. Finally, 19 active components from HT drug-containing serum were successfully identified, and we also unexpectedly discovered that HT might affect metabolic pathways such as proline and tyrosine metabolism, which have been reported to be involved in angiogenesis. HT has a promising effect on alleviating RA angiogenesis, at least in part through HIF1A-VEGFA-ANGPT axis inhibition, which reduces the cross-talk between RA-FLS and HUVECs. Our results suggest that HT is a drug candidate for the treatment of RA angiogenesis.

16 February 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
HDHaifang Du
Haifang Du
TTTing Tao
Ting Tao
SXSimeng Xu
Simeng Xu
CXChangqiong Xu
Changqiong Xu
SLShan Li
Shan Li
RLRan Li
Ran Li
Bladder cancer (BC) ranks the fourth in incidence in cancers of men and is a common malignant tumor in women. 4-Methoxydalbergione (4MOD), which is purified from Dalbergia sissoo Roxb, has been shown to have anticancer capacity for osteosarcoma and astroglioma. The role of 4MOD in bladder cancer has not been investigated. This study aims to evaluate the anticancer effect of 4MOD in BC cells and its possible mechanisms. The two human bladder cancer cell lines J82 and UMUC3 were used to evaluate the proliferation inhibitory effect of 4MOD by CCK8 and clonogenic assays. The migratory and invasive ability of tumor cells was examined by scratch test and transwell assay. Apoptosis was detected by flow cytometry and TUNEL assays. The autophagy-related molecules including Beclin-1 and LC3 were examined by Western blotting analysis. Furthermore, the RT-PCR was used to detect the mRNA expression of LC3. 4MOD repressed cell proliferation, migration, invasion and induced cell apoptosis in a concentration-dependent manner. The IC50 values of J82 and UMUC3 were 8.17 and 14.50 μM respectively. The mRNA and protein expression ratio of light chain 3-II (LC3-II)/LC3-I and the protein expression of Beclin-1 were increased when the BC cells were treated with 4MOD. The treatment of 4MOD attenuated the phosphorylation of Akt and ERK in the BC cells. We revealed that the 4MOD inhibits BC cells growth by inducing autophagy and inhibiting Akt/ERK signaling pathway. Our study provides new insights into the mechanism by which 4MOD weakens the proliferation of BC cells. This study demonstrates that 4MOD provided a lead compound for the development of novel compound with potent anticancer effect on BC cells.

15 September 2025 in Cancer Medicine
Verified
Journal Article
Open access
XHXiaotong Huang
Xiaotong Huang
XWXuan Wang
Xuan Wang
ZHZihe He
Zihe He
YHYishu Huang
Yishu Huang
BHBing Hu
Bing Hu
HDHaifang Du
Haifang Du
Background: Bacillus Calmette–Guérin (BCG) is the standard adjuvant therapy for high‐risk non‐muscle invasive bladder cancer (NMIBC), yet treatment failure occurs in 30% to 40% of patients. Those with BCG‐unresponsive disease face a high risk of progression and represent a critical unmet need in urologic oncology. This review summarizes the mechanisms of BCG failure and evaluates emerging therapies for BCG‐unresponsive NMIBC. Methods: We conducted a comprehensive literature review of clinical trials and preclinical studies through August 2025, focusing on therapeutic strategies for BCG‐unresponsive NMIBC. Mechanisms of BCG resistance, regulatory definitions, and results from recent Phase II/III trials were analyzed. Results: Multiple novel therapies have demonstrated efficacy in BCG‐unresponsive patients. Immune checkpoint inhibitors (e.g., pembrolizumab) achieved complete response (CR) rates of 41% in carcinoma in situ (CIS) patients. Gene therapies such as nadofaragene firadenovec and CG0070 induced CR rates of 51% and 75%, respectively. Device‐assisted therapies including hyperthermic intravesical chemotherapy (HIVEC) showed 24‐month recurrence‐free survival of 57.4%. The IL‐15 superagonist Anktiva (nogapendekin alfa inbakicept), recently FDA‐approved, achieved a 71% CR rate with a median duration of 26.6 months when combined with BCG. Conclusions: The treatment landscape for BCG‐unresponsive NMIBC is rapidly evolving, with immune checkpoint inhibitors, gene therapies, targeted agents, and advanced drug delivery systems showing promising efficacy. These innovations provide bladder‐preserving options for patients ineligible for radical cystectomy. Future directions include biomarker‐driven therapy selection, combination regimens, and optimized intravesical delivery platforms to improve long‐term outcomes.

1 February 2021 in Phytochemistry Letters
Verified
Journal Article
Closed access
HDHaifang Du
Haifang Du
HLHanxiang Li
Hanxiang Li
PWPing Wu
Ping Wu
CWChen Wang
Chen Wang
JXJinghua Xue
Jinghua Xue
XWXiaoyi Wei
Xiaoyi Wei

1 January 2025 in Human Mutation
Verified
Journal Article
Open access
LYLu Yang
Lu Yang
CBChunping Bo
Chunping Bo
MCMeiqi Chen
Meiqi Chen
BCBozhen Chen
Bozhen Chen
RZRui Zeng
Rui Zeng
XHXiaohong He
Xiaohong He
Objective: Ankylosing spondylitis (AS) is a long‐term inflammatory condition characterized by intricate pathogenesis and significant genetic predisposition. Current treatment methods cannot completely halt the progression of the disease. The purpose of this research is to discover possible therapeutic targets for AS by integrating Mendelian Randomization (MR), transcriptomics analysis, and machine learning, providing new options for the clinical treatment of AS.Methods: In this study, we initially pinpointed differentially expressed genes (DEGs) linked to AS from the GEO database and acquired cis‐eQTL data for these genes from the eQTLGen Consortium. Using MR and summary data–based Mendelian randomization (SMR) analyses, we screened for DEGs with causal relationships to AS. Subsequently, we analyzed the correlation between these causal genes and immune cell expression, constructed a risk prediction model, and identified key feature genes for AS. Next, we conducted phenome‐wide association studies (PheWASs) on the identified AS feature genes to predict their potential adverse effects as therapeutic targets. We obtained AS‐related therapeutic drugs from the DrugBank database and performed molecular docking analysis with AS feature genes. We used the CAIA collagen‐induced AS mouse model; we measured joint swelling and employed microCT, H&E, and Safranin O‐Fast Green staining to assess pathological changes in bone tissue. Additionally, we employed Western blot and RT‐qPCR to analyze the expression levels of genes associated with bone mineralization and AS feature genes in joint tissues.Results: A total of 1607 DEGs were obtained from the GEO database. After MR analysis and correction, 33 positive DEGs that have a causal relationship with AS were determined. Through the correlation analysis between these genes and the expressions of immune cells, it was found that 28 genes had significant regulatory relationships with 19 kinds of immune cells, with 55 pairs of negative regulatory relationships and 49 pairs of positive regulatory relationships, respectively. Four machine learning model algorithms determined the Top 5 genes (RIOK1, FUCA2, COL9A2, USP16, and TTC16) with the highest importance scores and constructed a nomogram to evaluate the risk probability. The results of the PheWAS showed that the five characteristic genes of AS had harmful or beneficial effects on numerous disease phenotypes of multiple types of diseases. Molecular docking indicated that 14 known AS treatment drugs had potential interactions with related genes. Using RT‐qPCR, we evaluated the expression levels of five key genes in the joint tissue of the CAIA collagen‐induced AS mouse model. Compared to the normal control group, we found that the levels of FUCA2 and USP16 were significantly elevated, while the levels of TTC16 were significantly reduced. In contrast, the expression of COL9A2 and RIOK1 mRNA showed no significant difference.Conclusion: Our research findings demonstrate that FUCA2, USP16, and TTC16 may serve as biomarkers for AS.

26 March 2026 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
WCWeiying Chen
Weiying Chen
XLXiaocui Li
Xiaocui Li
BHBing Hu
Bing Hu
YHYishu Huang
Yishu Huang
JZJinlang Zhong
Jinlang Zhong
ZLZhigang Liu
Zhigang Liu